Programme - Lymphocyte Engineering Conference

Programme

You can be part of the main session programme! The best abstracts will be presented alongside the top speakers in the field.

To view the abstract topics, visit the Delegate Abstract Submission page here.

programme.png

Programme Overview 

Thursday, 13 September 2018

11:00 - 13:00 
CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES


  • Accelerating the  Evolution of Cell Therapy
    Malcolm Brenner
    Founding Director at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, USA
  • TBC
    Michal Besser
    Head of Laboratory, Ella Lemelbaum Institute for Immuno Oncology, Sheba Medical Center, Israel
  • CAR-T Therapy for B cell malignancies
    Jenifer Brogdon
    Director, Exploratory Immuno-Oncology, Novartis Institutes for Biomedical Research, USA 
  • Xcellerate - Nextgen manufacturing platform for improved CAR T cells
    Lothar Germeroth
    SVP Juno Therapeutics, Inc., USA

13:00 - 14:30Lunch, Networking & Exhibition 
14:30 - 16:30
FIGHTING SOLID TUMORS WITH ENGINEERED LYMPHOCYTES

  • Targeting of multiple tumors and viral-infected cells using T-cells engineered to express NCR-based chimeric receptors
    Cyrille Cohen
    Associeate Professor at Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Israel
  • T cell receptor gene therapy
    Thomas Blankenstein
    Head of Molecular Immnology and Gene Therapy at Max-Delbrück-Center for Molecular Medicine (MDC), Germany
  • Engineering T cells for the Immunotherapy of Solid Tumors
    Stephen Gottschalk
    Chair of the Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, USA
  • CAR T cells in Glioblastoma and other Solid Tumors
    Marcela Maus
    Director, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center , Assistant Professor of Medicine, Harvard Medical School, Associate Member, Broad Institute of MIT and Harvard, USA
16:30 - 17:30Poster viewing and coffee break
17:30 - 19:30NON VIRAL VECTORS AND TRANSPOSONS

  • Engineering lymphocytes with RNAi nanomedicines
    Dan Peer
    Director, Tel Aviv University Cancer Biology Research Center,  Director, Laboratory of Precision NanoMedicine, Dept. of Cell Research & Immunology, and Dept. of Materials Science & Engineering,  Director, Leona M. and Harry B. Helmsley Nanotechnology Research Fund, Israel
  • New Targets and Technologies for CAR-T 
    Michael Hudecek
    Leading Hudecek Lab at Hospital of the University of Würzburg, Germany
  • Engineering T cells from bench to bed to boardroom
    Laurence Cooper
    Visiting Scientist at University of Texas MD Anderson Cancer Center Houston, Texas, Visiting Scientist, Department of Pediatrics Chief Executive Officer, ZIOPHARM Oncology, USA
19:30Welcome Reception


Friday, 14 September 2018

08:00 - 10:30
GENOME EDITING AND ALLOGENEIC ACT

  • Gene Edited Allogeneic T Cell Therapies  
    Waseem Qasim
    Professor of Cell and Gene Therapy, Institute of Child Helath, UCL, Consultant in Pediatric Immunology, Reader in Cell and Gene Therapy at Great Ormond Street Hospital for Children NHS Trust, UK
  • TBC
    Ayal Hendel
    Principal Investigator at Bar-Ilan University, Israel
  • CAR T Cell Therapy: the CD19 Paradigm 
    Xiuyan Wang

    Assistant Director, Michael G.Harris Cell Therapy and Cell Engineering Facility, USA 

  • Gene Edited Universal Off-the-shelf Immunotherapies: A Future-defining Shift in Simplicity, Availability, and Cost-effectiveness
    André Choulika
    Chairman & CEO of Cellectis Inc., USA

10:30 - 11:00Coffee Break, Exhibition & Networking
11:00 - 13:00NEW HORIZONS FOR LYMPHOCYTE AND HSC ENGINEERING

  • Highly efficient editing of primary human blood cells by homologous recombination
    Matthew Porteus
    Associate Professor of Pediatrics (Stem cell transplantation) at Stanford University, USA
  • Engineering Regulatory T-cell Therapeutics
    Andrew Scharenberg
    Chief Scientific Officer, Casebia Therapeutics; Professor, Department of Pediatrics, University of Washington, Attending Physician, Seattle Children's Hospital, USA
13:00 - 14:30Lunch, Networking & Exhibition 
14:30 - 16:00ENGINEERING LYMPHOCYTES TO CLEAR INFECTIONS

  • Engineering Resistance and Persistence - T Cells Fight Back Against HIV
    Bruce Levine
    Barbara and Edward Netter Professor in Cancer Gene Therapy Founding Director, Clinical Cell and Vaccine Production Facility Center for Cellular Immunotherapies Deputy Director – Technology Innovation and Assessment Department of Pathology and Laboratory Medicine Perelman School of Medicine, Abramson Cancer Center, University of Pennsylvania, USA
  • Engineering HSC and lymphocytes to suppress HIV
    Paula Cannon
    Professor of Molecular Microbiology and Immunobiology at Keck School of Medicine of University of Southern California, USA
  • Engineering Antiviral CAR T Cell Immunity through Hematopoietic Stem/Progenitor Cells
    Scott Kitchen
    Director, UCLA Humanized Mouse Core Laboratory, Division of Hematology/Oncology, The David Geffen School of Medicine, UCLA, USA
16:00 - 17:30Poster Viewing and coffee break
17:30 - 19:00
OPTIMIZING RECEPTOR AND VECTOR DESIGN 

  • From a cancer causing virus to a safer tool for gene therapy and immunotherapeutics
    Axel Schambach
    Director, Institute for Experimental Hematology, Hannover Medical School, Germany
  • Receptor-targeted viral vectors in immunotherapy
    Christian Buchholz
    Head of Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Germany

  • Clinical Trials Using CD19-targeting, Third Generation CAR T Cells with CD28 and 4-1BB Signaling Domains in Patients with B Cell Malignancy 
    Angelica Loskog
    Professor of Immunotherapy (adjunct) Department of Immunology, Genetics and Pathology, Uppsala University, Sweden
19:00Social Networking 


Saturday, 15 September 2018

08:00 - 10:30
SAFETY SWITCHES & CONTROLLED EXPRESSION 

  • Strategies for quantitative control of redirected gene-engineered T cell activity
    Daniel Powell
    Associate Professor of Pathology and Laboratory Medicine,  Associate Professor of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, USA
  • Using mRNA for improving T cell performance in adoptive cell therapy
    Gideon Gross
    Head of Immunology Laboratoty, MIGAL Galilee Research Institute Ltd., Senior faculty member at Tel-Hai College in the Upper Galilee, Israel
  • Isolation and identification of optimal T cells and receptors for adoptive immunotherapy
    Dirk Busch
    Director at the Institute for Med. Microbiology, Immunology and Hygene Technical University of Munich, Germany
10:30 - 11:00Coffee Break, Exhibition & Networking
11:00 - 13:00
NEW TARGETS AND NEW RECEPTORS

  • Designer T cells for Immunotherapy of Cancer
    Wolfgang Uckert
    Head of Department on Molecular Cell Biology and Gene Therapy at Max-Delbrück-Center for Molecular Medicine (MDC), Germany
  • p32, a novel target of CAR T-cell therapy for gliomas
    Dinora Friedmann-Morvinski
    Senior Lecturer at Tel Aviv University, Israel
  • Days of Thunder: Challenges When Seeking New CARs
    Barbara Savoldo
    Associate Director for the UC Lineberger, Immunotherapy Program at UNC Chapel Hill, NC Lineberger Comprehensive Cancer Center Professor in Immunology, Virology and Pediatrics Hem-Oncology, University of North Carolina at Chapel Hill, USA
13:00 - 14:30Lunch, Networking & Exhibition 
14:30 - 16:00CONCLUDING KEYNOTE LECTURES
  • TBC
    Carl June
    Director, Center for Cellular Immunotherapies;Director, Parker Institute Cancer Immunotherapy, Pathology and Laboratory Medicine department University of Pennsylvania, USA
  • TBC
    Zelig Eshhar
    The Marshall and Renette Erzalow Professor of chemical and Cellular Immunology, Weizmann Institute of Science, Israel
  • What's Next? From Personalized to "off the shelf" CARs
    Anat Globerson Levin
    Director and Senior scientists, Immunology Research Lab, Tel-Aviv Sourasky Medical Center, Israel 

  • Panel Discusson: Lymphocyte engineering - what's next?